Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced hepatocellular carcinoma. Considering diffe...

詳細記述

保存先:
書誌詳細
出版年:Ther Adv Med Oncol
主要な著者: He, Min-Ke, Liang, Run-Bin, Zhao, Yang, Xu, Yu-Jie, Chen, Huan-Wei, Zhou, Yuan-Min, Lai, Zhi-Cheng, Xu, Li, Wei, Wei, Zhang, Yao-Jun, Chen, Min-Shan, Guo, Rong-Ping, Li, Qi-Jiong, Shi, Ming
フォーマット: Artigo
言語:Inglês
出版事項: SAGE Publications 2021
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010824/
https://ncbi.nlm.nih.gov/pubmed/33854567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211002720
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料